Voyager Therapeutics said Tuesday it has appointed Jane Pritchett Henderson as senior vice president and chief financial officer effective Jan. 1.
Henderson most recently served as chief financial and business officer of Kolltan Pharmaceuticals, having joined the privately-held biopharmaceutical company in 2013 and leading the sale of Kolltan to Celldex Pharmaceuticals in late 2016.
According to SEC filings by the company, Henderson will receive a base annual salary of $370,000 and will be eligible to receive an annual performance bonus targeted at 30% of her base salary. She will also receive $50,000 in annual living assistance payments and reimbursement for a realtor’s fee on an apartment rental.
In connection with her hiring, Henderson will receive an option to purchase 214,000 shares of the company’s common stock (with a per-share exercise price equal to the closing price of the company’s common stock on the NASDAQ Global Select Market on the date of grant), with a 10-year term.